Physician profile
Steven V Stryk
NPI 1285637165
$948,686.07
in general payments reported to CMS, 2019-2025
16 companies · $144K in 2025
The $144K reported for 2025 was more than what 98% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88K · 2020: $72K · 2021: $143K · 2022: $141K · 2023: $193K · 2024: $167K · 2025: $144K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $457K · Travel and Lodging: $27K · Food and Beverage: $12K · Consulting Fee: $8,128 · Education: $87.21 · Gift: $17.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $456,955.13 |
| Travel and Lodging | $26,984.74 |
| Food and Beverage | $12,104.13 |
| Consulting Fee | $8,127.50 |
| Education | $87.21 |
| Gift | $17.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $629,967.67 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $86,168.76 | 2019-2025 | Dupixent |
| Genzyme Corporation | $76,013.77 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $69,663.55 | 2020-2025 | Cuvitru, Hyqvia, Takhzyro |
| Grifols USA, LLC | $28,401.92 | 2020-2024 | Xembify |
| Astrazeneca Pharmaceuticals Lp | $26,563.54 | 2019-2021 | |
| Shire North American Group INC | $16,006.14 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $7,920.00 | 2021 | |
| Genentech USA, INC. | $3,428.13 | 2020-2025 | Xolair |
| Biocryst Pharmaceuticals, INC. | $2,750.00 | 2020 | |
| Blueprint Medicines Corporation | $1,260.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $411.57 | 2022-2025 | |
| Amgen INC. | $74.85 | 2025 | Tezspire |
| Bio Products Laboratory USA, INC. | $31.30 | 2022 | |
| Biocryst US Sales Co., LLC | $17.19 | 2023 | Orladeyo |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $7.68 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Stryk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.